Gender differences in long-term beneficial effects of erythropoietin given after neonatal stroke in postnatal day-7 rats

T. C. Wen, M. Rogido, H. Peng, T. Genetta, J. Moore, A. Sola

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Recently, we reported that erythropoietin attenuates neonatal brain injury caused by focal cerebral ischemia. The long-term effects of erythropoietin on focal cerebral ischemia-induced injury to the developing brain and the potential gender differences in these long-term effects have not been studied in detail. The current study demonstrated a similarity in the mean infarct volume in both the vehicle-treated male and female rats at 6 and 12 weeks after focal cerebral ischemia. On the other hand, erythropoietin treatment (1000 U/kg×three doses after focal cerebral ischemia) caused a significant reduction in the mean infarct volume in both males and females at 6 weeks after focal cerebral ischemia when compared with the corresponding vehicle-treated animals (males: 141.4±48.2 mm3 vs. 194.0±59.2 mm3, P<0.05; females: 85.4±31.6 mm3 vs. 183.4±46.3 mm3, P<0.05). Interestingly, the reduction in the mean infarct volume in the erythropoietin-treated males was significantly less than that in the erythropoietin-treated females at 6 weeks after focal cerebral ischemia (141.4±48.2 mm3 vs. 85.4±31.6 mm3, P<0.05). At 12 weeks after focal cerebral ischemia, the mean infarct volume in the erythropoietin-treated males significantly increased to 181.0±50.4 mm3 (P<0.05). In contrast, the mean infarct volume in the erythropoietin-treated females remained stable (87.0±41.7 mm3). Additionally, erythropoietin treatment significantly improved sensorimotor function recovery with a misstep number similar to the sham-operation group at 6 and 12 weeks after focal cerebral ischemia. Moreover, the mean number of missteps in the erythropoietin-treated females was less than that in males at 6 (13.5±2.0 vs. 24.5±2.5, P<0.05) and 12 (12.5±2.0 vs. 20.0±2.0, P<0.05) weeks after focal cerebral ischemia. These results indicate that erythropoietin administration after focal cerebral ischemia produces a significant long-term neuroprotective benefit on the developing brain, and that this effect is more beneficial in the female rats.

Original languageEnglish (US)
Pages (from-to)803-811
Number of pages9
JournalNeuroscience
Volume139
Issue number3
DOIs
StatePublished - 2006

Fingerprint

Erythropoietin
Brain Ischemia
Stroke
Recovery of Function
Brain
Brain Injuries
Wounds and Injuries

Keywords

  • erythropoietin
  • gender differences
  • neonatal focal stroke
  • neuroprotection

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Gender differences in long-term beneficial effects of erythropoietin given after neonatal stroke in postnatal day-7 rats. / Wen, T. C.; Rogido, M.; Peng, H.; Genetta, T.; Moore, J.; Sola, A.

In: Neuroscience, Vol. 139, No. 3, 2006, p. 803-811.

Research output: Contribution to journalArticle

Wen, T. C. ; Rogido, M. ; Peng, H. ; Genetta, T. ; Moore, J. ; Sola, A. / Gender differences in long-term beneficial effects of erythropoietin given after neonatal stroke in postnatal day-7 rats. In: Neuroscience. 2006 ; Vol. 139, No. 3. pp. 803-811.
@article{870d9bcdbbbd4719ab79d63153f0c990,
title = "Gender differences in long-term beneficial effects of erythropoietin given after neonatal stroke in postnatal day-7 rats",
abstract = "Recently, we reported that erythropoietin attenuates neonatal brain injury caused by focal cerebral ischemia. The long-term effects of erythropoietin on focal cerebral ischemia-induced injury to the developing brain and the potential gender differences in these long-term effects have not been studied in detail. The current study demonstrated a similarity in the mean infarct volume in both the vehicle-treated male and female rats at 6 and 12 weeks after focal cerebral ischemia. On the other hand, erythropoietin treatment (1000 U/kg×three doses after focal cerebral ischemia) caused a significant reduction in the mean infarct volume in both males and females at 6 weeks after focal cerebral ischemia when compared with the corresponding vehicle-treated animals (males: 141.4±48.2 mm3 vs. 194.0±59.2 mm3, P<0.05; females: 85.4±31.6 mm3 vs. 183.4±46.3 mm3, P<0.05). Interestingly, the reduction in the mean infarct volume in the erythropoietin-treated males was significantly less than that in the erythropoietin-treated females at 6 weeks after focal cerebral ischemia (141.4±48.2 mm3 vs. 85.4±31.6 mm3, P<0.05). At 12 weeks after focal cerebral ischemia, the mean infarct volume in the erythropoietin-treated males significantly increased to 181.0±50.4 mm3 (P<0.05). In contrast, the mean infarct volume in the erythropoietin-treated females remained stable (87.0±41.7 mm3). Additionally, erythropoietin treatment significantly improved sensorimotor function recovery with a misstep number similar to the sham-operation group at 6 and 12 weeks after focal cerebral ischemia. Moreover, the mean number of missteps in the erythropoietin-treated females was less than that in males at 6 (13.5±2.0 vs. 24.5±2.5, P<0.05) and 12 (12.5±2.0 vs. 20.0±2.0, P<0.05) weeks after focal cerebral ischemia. These results indicate that erythropoietin administration after focal cerebral ischemia produces a significant long-term neuroprotective benefit on the developing brain, and that this effect is more beneficial in the female rats.",
keywords = "erythropoietin, gender differences, neonatal focal stroke, neuroprotection",
author = "Wen, {T. C.} and M. Rogido and H. Peng and T. Genetta and J. Moore and A. Sola",
year = "2006",
doi = "10.1016/j.neuroscience.2006.02.057",
language = "English (US)",
volume = "139",
pages = "803--811",
journal = "Neuroscience",
issn = "0306-4522",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Gender differences in long-term beneficial effects of erythropoietin given after neonatal stroke in postnatal day-7 rats

AU - Wen, T. C.

AU - Rogido, M.

AU - Peng, H.

AU - Genetta, T.

AU - Moore, J.

AU - Sola, A.

PY - 2006

Y1 - 2006

N2 - Recently, we reported that erythropoietin attenuates neonatal brain injury caused by focal cerebral ischemia. The long-term effects of erythropoietin on focal cerebral ischemia-induced injury to the developing brain and the potential gender differences in these long-term effects have not been studied in detail. The current study demonstrated a similarity in the mean infarct volume in both the vehicle-treated male and female rats at 6 and 12 weeks after focal cerebral ischemia. On the other hand, erythropoietin treatment (1000 U/kg×three doses after focal cerebral ischemia) caused a significant reduction in the mean infarct volume in both males and females at 6 weeks after focal cerebral ischemia when compared with the corresponding vehicle-treated animals (males: 141.4±48.2 mm3 vs. 194.0±59.2 mm3, P<0.05; females: 85.4±31.6 mm3 vs. 183.4±46.3 mm3, P<0.05). Interestingly, the reduction in the mean infarct volume in the erythropoietin-treated males was significantly less than that in the erythropoietin-treated females at 6 weeks after focal cerebral ischemia (141.4±48.2 mm3 vs. 85.4±31.6 mm3, P<0.05). At 12 weeks after focal cerebral ischemia, the mean infarct volume in the erythropoietin-treated males significantly increased to 181.0±50.4 mm3 (P<0.05). In contrast, the mean infarct volume in the erythropoietin-treated females remained stable (87.0±41.7 mm3). Additionally, erythropoietin treatment significantly improved sensorimotor function recovery with a misstep number similar to the sham-operation group at 6 and 12 weeks after focal cerebral ischemia. Moreover, the mean number of missteps in the erythropoietin-treated females was less than that in males at 6 (13.5±2.0 vs. 24.5±2.5, P<0.05) and 12 (12.5±2.0 vs. 20.0±2.0, P<0.05) weeks after focal cerebral ischemia. These results indicate that erythropoietin administration after focal cerebral ischemia produces a significant long-term neuroprotective benefit on the developing brain, and that this effect is more beneficial in the female rats.

AB - Recently, we reported that erythropoietin attenuates neonatal brain injury caused by focal cerebral ischemia. The long-term effects of erythropoietin on focal cerebral ischemia-induced injury to the developing brain and the potential gender differences in these long-term effects have not been studied in detail. The current study demonstrated a similarity in the mean infarct volume in both the vehicle-treated male and female rats at 6 and 12 weeks after focal cerebral ischemia. On the other hand, erythropoietin treatment (1000 U/kg×three doses after focal cerebral ischemia) caused a significant reduction in the mean infarct volume in both males and females at 6 weeks after focal cerebral ischemia when compared with the corresponding vehicle-treated animals (males: 141.4±48.2 mm3 vs. 194.0±59.2 mm3, P<0.05; females: 85.4±31.6 mm3 vs. 183.4±46.3 mm3, P<0.05). Interestingly, the reduction in the mean infarct volume in the erythropoietin-treated males was significantly less than that in the erythropoietin-treated females at 6 weeks after focal cerebral ischemia (141.4±48.2 mm3 vs. 85.4±31.6 mm3, P<0.05). At 12 weeks after focal cerebral ischemia, the mean infarct volume in the erythropoietin-treated males significantly increased to 181.0±50.4 mm3 (P<0.05). In contrast, the mean infarct volume in the erythropoietin-treated females remained stable (87.0±41.7 mm3). Additionally, erythropoietin treatment significantly improved sensorimotor function recovery with a misstep number similar to the sham-operation group at 6 and 12 weeks after focal cerebral ischemia. Moreover, the mean number of missteps in the erythropoietin-treated females was less than that in males at 6 (13.5±2.0 vs. 24.5±2.5, P<0.05) and 12 (12.5±2.0 vs. 20.0±2.0, P<0.05) weeks after focal cerebral ischemia. These results indicate that erythropoietin administration after focal cerebral ischemia produces a significant long-term neuroprotective benefit on the developing brain, and that this effect is more beneficial in the female rats.

KW - erythropoietin

KW - gender differences

KW - neonatal focal stroke

KW - neuroprotection

UR - http://www.scopus.com/inward/record.url?scp=33646121270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646121270&partnerID=8YFLogxK

U2 - 10.1016/j.neuroscience.2006.02.057

DO - 10.1016/j.neuroscience.2006.02.057

M3 - Article

C2 - 16581190

AN - SCOPUS:33646121270

VL - 139

SP - 803

EP - 811

JO - Neuroscience

JF - Neuroscience

SN - 0306-4522

IS - 3

ER -